A detailed history of Geode Capital Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,810,526 shares of APLS stock, worth $61.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,810,526
Previous 1,787,917 1.26%
Holding current value
$61.6 Million
Previous $68.6 Million 23.87%
% of portfolio
0.0%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$28.84 - $41.15 $652,043 - $930,360
22,609 Added 1.26%
1,810,526 $52.2 Million
Q2 2024

Aug 09, 2024

BUY
$38.07 - $59.71 $3.73 Million - $5.85 Million
98,027 Added 5.8%
1,787,917 $68.6 Million
Q1 2024

May 13, 2024

BUY
$55.39 - $72.47 $3.28 Million - $4.29 Million
59,248 Added 3.63%
1,689,890 $99.3 Million
Q4 2023

Feb 13, 2024

BUY
$37.14 - $64.82 $2.82 Million - $4.91 Million
75,816 Added 4.88%
1,630,642 $97.6 Million
Q3 2023

Nov 13, 2023

BUY
$23.65 - $89.22 $1.33 Million - $5.04 Million
56,437 Added 3.77%
1,554,826 $59.1 Million
Q2 2023

Aug 11, 2023

SELL
$76.68 - $93.31 $26.1 Million - $31.7 Million
-339,890 Reduced 18.49%
1,498,389 $137 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $4.11 Million - $5.91 Million
88,278 Added 5.04%
1,838,279 $121 Million
Q4 2022

Feb 13, 2023

BUY
$43.24 - $61.04 $2.54 Million - $3.59 Million
58,799 Added 3.48%
1,750,001 $90.5 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $3.63 Million - $5.65 Million
81,040 Added 5.03%
1,691,202 $116 Million
Q2 2022

Aug 12, 2022

BUY
$35.07 - $59.21 $4.09 Million - $6.91 Million
116,642 Added 7.81%
1,610,162 $72.8 Million
Q1 2022

May 13, 2022

BUY
$35.46 - $54.12 $4.99 Million - $7.61 Million
140,691 Added 10.4%
1,493,520 $75.9 Million
Q4 2021

Feb 11, 2022

BUY
$30.74 - $49.16 $5.05 Million - $8.08 Million
164,437 Added 13.84%
1,352,829 $64 Million
Q3 2021

Nov 12, 2021

BUY
$31.4 - $69.84 $2.21 Million - $4.91 Million
70,257 Added 6.28%
1,188,392 $39.2 Million
Q2 2021

Aug 13, 2021

BUY
$40.9 - $64.9 $2.91 Million - $4.62 Million
71,222 Added 6.8%
1,118,135 $70.7 Million
Q1 2021

May 12, 2021

BUY
$40.8 - $57.39 $4.5 Million - $6.33 Million
110,380 Added 11.79%
1,046,913 $44.9 Million
Q4 2020

Feb 12, 2021

BUY
$30.79 - $57.2 $1.81 Million - $3.36 Million
58,719 Added 6.69%
936,533 $53.6 Million
Q3 2020

Nov 13, 2020

BUY
$25.89 - $33.65 $308,505 - $400,973
11,916 Added 1.38%
877,814 $26.5 Million
Q2 2020

Aug 13, 2020

BUY
$24.8 - $38.49 $938,655 - $1.46 Million
37,849 Added 4.57%
865,898 $28.3 Million
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $3.05 Million - $7.54 Million
170,112 Added 25.86%
828,049 $22.2 Million
Q4 2019

Feb 13, 2020

BUY
$22.1 - $30.8 $689,232 - $960,559
31,187 Added 4.98%
657,937 $20.1 Million
Q3 2019

Nov 12, 2019

BUY
$24.09 - $32.18 $1.17 Million - $1.57 Million
48,753 Added 8.43%
626,750 $15.1 Million
Q2 2019

Aug 14, 2019

BUY
$18.0 - $25.34 $1.63 Million - $2.29 Million
90,565 Added 18.58%
577,997 $14.6 Million
Q1 2019

May 14, 2019

BUY
$12.81 - $19.82 $840,118 - $1.3 Million
65,583 Added 15.55%
487,432 $9.5 Million
Q4 2018

Feb 13, 2019

BUY
$11.47 - $18.71 $557,476 - $909,362
48,603 Added 13.02%
421,849 $5.56 Million
Q3 2018

Nov 13, 2018

BUY
$16.57 - $21.03 $216,139 - $274,315
13,044 Added 3.62%
373,246 $6.64 Million
Q2 2018

Aug 14, 2018

BUY
$19.63 - $30.0 $4.13 Million - $6.31 Million
210,210 Added 140.15%
360,202 $7.92 Million
Q1 2018

May 15, 2018

BUY
$14.01 - $26.02 $53,195 - $98,797
3,797 Added 2.6%
149,992 $3.32 Million
Q4 2017

Feb 13, 2018

BUY
$12.71 - $21.7 $1.86 Million - $3.17 Million
146,195
146,195 $3.17 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.74B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.